Effects of long-term pravastatin treatment on serum and urinary monocyte chemoattractant protein-1 levels and renal function in type 2 diabetic patients with normoalbuminuria

被引：4

作者：

Fujita, Hiroki ^{[1
]}

Koshimura, Jun ^{[1
]}

Sato, Takehiro ^{[1
]}

Miura, Takeshi ^{[1
]}

Sasaki, Hiroshi ^{[1
]}

Morii, Tsukasa ^{[1
]}

Narita, Takuma ^{[1
]}

Kakei, Masafumi ^{[1
]}

Ito, Seiki ^{[1
]}

Yamada, Yuichiro ^{[1
]}

机构：

[1] Akita Univ, Sch Med, Dept Internal Med, Div Endocrinol Metab & Geriatr Med, Akita 0108543, Japan

来源：

RENAL FAILURE | 2007年 / 29卷 / 07期

关键词：

pravastatin; monocyte chemoattractant protein-1; type; 2; diabetes; normoalbuminuria; low-density lipoprotein cholesterol;

D O I：

10.1080/08860220701543056

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

To explore the renoprotective and anti-inflammatory effects of pravastatin, we analyzed the changes in renal function and urinary monocyte chemoattractant protein-1 (MCP-1) level as a renal tubulointerstitial inflammatory biomarker and serum MCP-l level as a systemic inflammatory biomarker following the introduction of treatment with 10 mg/day of pravastatin in 10 hyperlipidemic type 2 diabetic patients with normoalbuminuria. Twelve months of the pravastatin treatment did not affect urinary levels of albumin, transferrin, N-acetylglucosaminidase, or MCP-1 in the hyperlipidemic diabetic patients, whereas the treatment significantly reduced serum levels of MCP-1 in the patients. The pravastatin treatment effectively lowered low-density lipoprotein cholesterol (LDL-C) levels in the hyperlipidemic diabetic patients to levels nearly to those in 11 non-hyperlipidemic type 2 diabetic patients with normoalbuminuria. Interestingly, serum MCP-1 levels were significantly lower in the hyperlipidermc patients treated with pravastatin than in the non-hyperlipidemic patients. No significant correlation was observed between serum LDL-C and MCP-1 levels in all the data in the hyperlipidemic patients before and after the pravastatin treatment and in the non-hyperlipidemic patients. These results collectively indicate that pravastatin may ameliorate systemic vascular inflammation rather than local renal inflammation in hyperlipidemic type 2 diabetic patients with normoalbuminuria, independent of its cholesterol-lowering effects.

引用

页码：791 / 796

页数：6

共 27 条

[1] Effect of statin therapy on C-reactive protein levels - The Pravastatin Inflammation/CRP Evaluation (PRINCE): A randomized trial and cohort study [J].